Meridian Bioscience - VIVO Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VIVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIVO, but not buy additional shares or sell existing shares.
View VIVO analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price objectives for Meridian Bioscience's shares. Their VIVO share price forecasts range from $34.00 to $34.00. On average, they expect the company's share price to reach $34.00 in the next year. This suggests a possible upside of 6.5% from the stock's current price.
View analysts price targets for VIVO or view top-rated stocks among Wall Street analysts.

Meridian Bioscience's stock was trading at $20.40 on January 1st, 2022. Since then, VIVO stock has increased by 56.5% and is now trading at $31.92.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our VIVO earnings forecast.

Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings results on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.03. The business earned $76.20 million during the quarter, compared to analysts' expectations of $68.40 million. Meridian Bioscience had a net margin of 12.58% and a trailing twelve-month return on equity of 17.55%. During the same period in the previous year, the firm posted $0.19 earnings per share.

Meridian Bioscience issued an update on its third quarter 2022 earnings guidance on Thursday, July, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $66.00 million-$69.00 million, compared to the consensus revenue estimate of $69.57 million.

7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Shares of VIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VIVO stock can currently be purchased for approximately $31.92.

Meridian Bioscience (NASDAQ:VIVO) has a market capitalization of $1.40 billion and generates $317.90 million in revenue each year. The company earns $71.41 million in net income (profit) each year or $0.99 on an earnings per share basis.

The company employs 702 workers across the globe.

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The official website for the company is www.meridianbioscience.com. The company can be reached via phone at (513) 271-3700, via email at mbi@meridianbioscience.com, or via fax at 513-271-3762.